SCHEMBL8097765

SCHEMBL8097765

Cc1ccccc1C(OC(C)N1CCNCC1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.48
SLC6A4 P31645 8/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CHRNA7 P36544 1/20 0.46
ESR1 P03372 1/20 0.44
CYP2D6 P10635 5/20 0.42
KCNH2 Q12809 4/20 0.42
HTR6 P50406 3/20 0.42
SLC6A3 Q01959 3/20 0.42
HTR7 P34969 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
CYP3A4 P08684 3/20 0.41
SLC22A2 O15244 1/20 0.41
SLC22A1 O15245 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255523 0.87 MEN1 (0.56) SLC6A2SLC6A4MEN1KMT2ACYP2D6
SCHEMBL5268174 0.75 ESR1 (0.75) SLC6A2SLC6A4MEN1KMT2ACHRNA7
SCHEMBL8097776 0.74 CHRNA7 (0.79) SLC6A2SLC6A4MEN1KMT2ACHRNA7
SCHEMBL8963664 0.73 MEN1 (0.56) SLC6A2SLC6A4MEN1KMT2ACYP2D6
SCHEMBL9818808 0.71 CYP2D6 (0.53) SLC6A2SLC6A4MEN1KMT2ACHRNA7
SCHEMBL4189112 0.70 SLC6A2 (0.48) SLC6A2SLC6A4CHRNA7ESR1CYP2D6
SCHEMBL42790 0.69 CYP2D6 (0.73) SLC6A2SLC6A4MEN1KMT2ACYP2D6
SCHEMBL3950480 0.69 CYP2D6 (0.73) SLC6A2SLC6A4MEN1KMT2ACYP2D6
SCHEMBL3956861 0.69 CYP2D6 (0.73) SLC6A2SLC6A4MEN1KMT2ACYP2D6
SCHEMBL7451551 0.68 MEN1 (0.50) SLC6A2SLC6A4MEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed